Cybin Renames to Helus Pharma and Moves to Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy ?
Cybin announced that the company will operate under the business name Helus Pharma and trade on Nasdaq with ticker symbol (HELP). The company has transferred its U.S. stock exchange listing from the NYSE American to the Nasdaq. The company will continue to be listed on the Cboe Canada and will trade under the same ticker symbol. The company expects to seek approval from shareholders to change its legal name to Helus Pharma at the company's next annual and special meeting of shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
